Talon seeks market approval for new vincristine formulation

Talon Therapeutics has submitted a new drug application (NDA) to the US FDA seeking accelerated approval of the company's leading drug candidate Marqibo (vincristine sulfate liposomes injection) and it has been accepted for filing.

The FDA will now review Marqibo as a potential treatment for adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or that has progressed following two or more lines of anti-leukemia therapy.

Recently, Talon received Special Protocol Assessment (SPA) agreement from the FDA for its proposed Phase III adult front-line study (called HALLMARQ) to treat adults aged 60 or older with newly diagnosed ALL.

Marqibo will also be explored in a Phase I-II clinical study conducted by the National Cancer Institute against pediatric cancers (solid tumors and lymphoid cancers), as well as against newly diagnosed, aggressive Non-Hodgkin's Lymphoma, in the latter case to be conducted by the prestigious German High Grade Non-Hodgkin's Lymphoma Study Group.

Marqibo is a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved drug vincristine, a chemotherapeutic microtubule inhibitor.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap